查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1597832

全身性红斑性狼疮市场：按药物类型、给药方法划分 - 全球预测 2025-2030

Systemic Lupus Erythematosus Market by Drug Type (Antimalarial Drugs, B-Cell Modulators, Biologics), Mode of Delivery (Intravenous, Oral, Subcutaneous) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年全身性红斑性狼疮市值为20.4亿美元，预计2024年将达22.4亿美元，复合年增长率为10.54%，预计到2030年将达到41.2亿美元。

全身性红斑性狼疮(SLE) 是自体免疫疾病，其特征是免疫系统攻击健康组织，引起身体各个系统的发炎和损伤。了解 SLE 市场的必要性在于疾病的不可预测性，以及由于其慢性进展而需要增强的治疗选择。这种需求正在推动精准医学、生物製药和个人化治疗方法的应用，使它们与医疗保健提供者和患者越来越相关。最终用途范围主要包括专注于创新治疗解决方案的医院、诊所和研究机构。推动市场开拓的关键因素包括盛行率上升、意识增强以及促进开发新药的生物技术进步。此外，诊断技术的改进正在扩大早期检测和开始治疗的范围，为涉足早期疗育解决方案的市场参与者创造了有利可图的机会。

主要市场统计
基准年[2023] 20.4亿美元
预测年份 [2024] 22.4亿美元
预测年份 [2030] 41.2亿美元
复合年增长率（%） 10.54%

目前 SLE 市场的潜在机会是生物製药和标靶治疗的成长，正在进行的研究为更有效的治疗和症状管理铺平了道路。创建以患者为中心的干预措施并与技术进步保持一致，例如利用人工智慧进行药物发现，是利用这些趋势的策略领域。儘管有这样的成长路径，但市场仍面临重大挑战，包括高昂的开发成本、监管障碍以及由于患者异质性而导致进行临床试验的复杂性。专利到期也可能影响市场动态，需要配方和药物输送系统的创新。

为了实现业务成长和创新，公司应优先考虑个人化医疗的生物标记发现、副作用较少的治疗方法以及利用现有和新型治疗方法的联合治疗研究等领域。 SLE 市场的本质是高度竞争和监管，成功应对这些挑战需要强大的研发投资和策略联盟。了解法律规范并投资加强临床开发能力是维持市场定位和成长的重要步骤。

市场动态：快速发展的全身性红斑性狼疮市场的关键市场洞察

全身性红斑性狼疮市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全身性红斑性狼疮的全球盛行率不断上升
    • 提高对发炎自体免疫疾病和治疗的认识
    • 改善医疗基础设施和狼疮治疗诊所
  • 市场限制因素
    • 低收入国家治疗成本上升和基础设施缺乏
  • 市场机会
    • 对狼疮研究工作的大量资助和投资
    • 治疗技术的进步与新产品的推出
  • 市场挑战
    • 治疗併发症和管理 SLE 的其他困难

波特五力：驾驭全身性红斑性狼疮市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解全身性红斑性狼疮市场的外部影响

外部宏观环境因素在塑造全身性红斑性狼疮市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解全身性红斑性狼疮市场的竞争状况

全身性红斑性狼疮市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵全身性红斑性狼疮市场供应商的绩效评估

FPNV定位矩阵是评估全身性红斑性狼疮市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製全身性红斑性狼疮市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，全身性红斑性狼疮市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球全身性红斑性狼疮盛行率增加
      • 提高对发炎自体免疫疾病和治疗的认识
      • 改善医疗基础设施和狼疮治疗诊所
    • 抑制因素
      • 低收入国家治疗成本上升和基础设施缺乏
    • 机会
      • 对狼疮研究工作的大量资助和投资
      • 治疗技术的进步与新产品的推出
    • 任务
      • 治疗併发症和管理 SLE 的其他困难
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章全身性红斑性狼疮市场药物类型

  • 抗疟疾药
    • Chloroquine
    • Chloroquine
  • B细胞调变器
  • 生物製药
    • 核准用于治疗 SLE 的生物製药
      • B细胞标靶治疗
      • Bryce 阻断剂（贝利尤单抗）
    • 仿单标示外使用的生物製药
  • 细胞毒性和免疫抑制药物
    • Cyclophosphamide
    • Cyclosporine
    • 胺基甲基叶酸
    • Mycophenolate Mofetil或Tacrolimus
  • 免疫抑制剂、细胞毒药物、T细胞调节剂
  • 非类固醇消炎剂
  • 发炎和细胞激素抑制剂

第七章以交付方式分類的全身性红斑性狼疮市场

  • 静脉
  • 口服
  • 皮下的
  • 话题

第八章北美和南美全身性红斑性狼疮市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区全身性红斑性狼疮市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第10章欧洲、中东和非洲的全身性红斑性狼疮市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbvie, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Aurinia Pharmaceuticals Inc.
  • bioMerieux SA
  • Boston Pharmaceuticals Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Hoffmann-LA-Roche Ltd.
  • ImmuPharma PLC
  • Mylan NV
  • Novartis AG
  • Pfizer, Inc.
  • Xencor, Inc.
Product Code: MRR-957C47F944B9

The Systemic Lupus Erythematosus Market was valued at USD 2.04 billion in 2023, expected to reach USD 2.24 billion in 2024, and is projected to grow at a CAGR of 10.54%, to USD 4.12 billion by 2030.

Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by the immune system attacking healthy tissues, leading to inflammation and damage across various body systems. The necessity of understanding the SLE market lies in the need for enhanced therapeutic options due to the disease's unpredictable nature and chronic progression. This demand is driving the application of precision medicine, biologics, and personalized treatment regimens, which are becoming increasingly relevant for both healthcare providers and patients. The end-use scope primarily involves hospitals, clinics, and research institutions focusing on innovative treatment solutions. Key market growth influencers include rising prevalence rates, increased awareness, and advancements in biotechnology facilitating novel drug development. Additionally, improved diagnostic techniques are expanding earlier detection and treatment initiation, presenting lucrative opportunities for market players to venture into early intervention solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 2.04 billion
Estimated Year [2024] USD 2.24 billion
Forecast Year [2030] USD 4.12 billion
CAGR (%) 10.54%

Current potential opportunities in the SLE market embrace growth in biologics and targeted therapies, with ongoing research paving the way for more effective treatments and symptom management. The creation of patient-focused interventions and alignment with technological advancements, such as using AI for drug discovery, are strategic areas for capitalizing on these trends. Despite these growth avenues, the market faces significant challenges, including high development costs, regulatory hurdles, and the complexity of conducting clinical trials due to patient heterogeneity. Patent expirations may also impact market dynamics, necessitating innovation in drug formulations and delivery systems.

For business growth and innovation, companies should prioritize areas such as biomarker discovery for personalized medicine, reduced side-effect therapies, and research into combination therapies that leverage existing and new modalities. The SLE market's nature is highly competitive and regulated, necessitating robust R&D investments and strategic partnerships to navigate these challenges successfully. Understanding regulatory frameworks and investing in enhancing clinical development capabilities are essential steps to ensure sustained market positioning and growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Systemic Lupus Erythematosus Market

The Systemic Lupus Erythematosus Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of systemic lupus erythematosus worldwide
    • Rising awareness of inflammatory autoimmune diseases and treatment
    • Improvement in healthcare infrastructure and lupus treatment clinics
  • Market Restraints
    • High cost of treatment and lack of infrastructure in low-income countries
  • Market Opportunities
    • Significant funding and investment for lupus research activities
    • Advancement in treatment technologie and launch of new products
  • Market Challenges
    • Complications in treatment and other difficulties in managing SLE

Porter's Five Forces: A Strategic Tool for Navigating the Systemic Lupus Erythematosus Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Systemic Lupus Erythematosus Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Systemic Lupus Erythematosus Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Systemic Lupus Erythematosus Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Systemic Lupus Erythematosus Market

A detailed market share analysis in the Systemic Lupus Erythematosus Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Systemic Lupus Erythematosus Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Systemic Lupus Erythematosus Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Systemic Lupus Erythematosus Market

A strategic analysis of the Systemic Lupus Erythematosus Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Systemic Lupus Erythematosus Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Amgen Inc., AstraZeneca PLC, Aurinia Pharmaceuticals Inc., bioMerieux SA, Boston Pharmaceuticals Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline PLC, Hoffmann-LA-Roche Ltd., ImmuPharma PLC, Mylan N.V., Novartis AG, Pfizer, Inc., and Xencor, Inc..

Market Segmentation & Coverage

This research report categorizes the Systemic Lupus Erythematosus Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Antimalarial Drugs, B-Cell Modulators, Biologics, Cytotoxic & Immunosuppressive Drugs, Immunosuppressive & Cytotoxic Drugs & T-Cell Modulators, Non-Steroidal Anti-Inflammatory Drugs, and Pro-Inflammatory & Cytokine Inhibitors. The Antimalarial Drugs is further studied across Chloroquine and Hydrochloroquine. The Biologics is further studied across Approved Biologics for Treating SLE and Biologics Used Off-Label. The Approved Biologics for Treating SLE is further studied across B-Cell Targeted Therapy and Blys-Blockers (Belimumab). The Cytotoxic & Immunosuppressive Drugs is further studied across Cyclophosphamide, Cyclosporine, Methotrexate, and Mycophenolate Mofetil or Tacrolimus.
  • Based on Mode of Delivery, market is studied across Intravenous, Oral, Subcutaneous, and Topical.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of systemic lupus erythematosus worldwide
      • 5.1.1.2. Rising awareness of inflammatory autoimmune diseases and treatment
      • 5.1.1.3. Improvement in healthcare infrastructure and lupus treatment clinics
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and lack of infrastructure in low-income countries
    • 5.1.3. Opportunities
      • 5.1.3.1. Significant funding and investment for lupus research activities
      • 5.1.3.2. Advancement in treatment technologie and launch of new products
    • 5.1.4. Challenges
      • 5.1.4.1. Complications in treatment and other difficulties in managing SLE
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Systemic Lupus Erythematosus Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Antimalarial Drugs
    • 6.2.1. Chloroquine
    • 6.2.2. Hydrochloroquine
  • 6.3. B-Cell Modulators
  • 6.4. Biologics
    • 6.4.1. Approved Biologics for Treating SLE
      • 6.4.1.1. B-Cell Targeted Therapy
      • 6.4.1.2. Blys-Blockers (Belimumab)
    • 6.4.2. Biologics Used Off-Label
  • 6.5. Cytotoxic & Immunosuppressive Drugs
    • 6.5.1. Cyclophosphamide
    • 6.5.2. Cyclosporine
    • 6.5.3. Methotrexate
    • 6.5.4. Mycophenolate Mofetil or Tacrolimus
  • 6.6. Immunosuppressive & Cytotoxic Drugs & T-Cell Modulators
  • 6.7. Non-Steroidal Anti-Inflammatory Drugs
  • 6.8. Pro-Inflammatory & Cytokine Inhibitors

7. Systemic Lupus Erythematosus Market, by Mode of Delivery

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Oral
  • 7.4. Subcutaneous
  • 7.5. Topical

8. Americas Systemic Lupus Erythematosus Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Systemic Lupus Erythematosus Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Systemic Lupus Erythematosus Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie, Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Aurinia Pharmaceuticals Inc.
  • 5. bioMerieux SA
  • 6. Boston Pharmaceuticals Inc.
  • 7. Bristol-Myers Squibb Company
  • 8. Eli Lilly and Company
  • 9. GlaxoSmithKline PLC
  • 10. Hoffmann-LA-Roche Ltd.
  • 11. ImmuPharma PLC
  • 12. Mylan N.V.
  • 13. Novartis AG
  • 14. Pfizer, Inc.
  • 15. Xencor, Inc.

LIST OF FIGURES

  • FIGURE 1. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET RESEARCH PROCESS
  • FIGURE 2. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET DYNAMICS
  • TABLE 7. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CHLOROQUINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY HYDROCHLOROQUINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY B-CELL MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY B-CELL TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BLYS-BLOCKERS (BELIMUMAB), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS USED OFF-LABEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MYCOPHENOLATE MOFETIL OR TACROLIMUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY IMMUNOSUPPRESSIVE & CYTOTOXIC DRUGS & T-CELL MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY PRO-INFLAMMATORY & CYTOKINE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 284. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 285. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, FPNV POSITIONING MATRIX, 2023